Compare AbCellera Biologics Inc (ABCL) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Old Dominion Freight Line Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Old Dominion Freight Line Inc trades at $217.16 (market cap $44.82B). The key difference: Old Dominion Freight Line Inc is far larger — about 19.1× AbCellera Biologics Inc's market cap, and Old Dominion Freight Line Inc pays a 0.54% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ODFL | |
|---|---|---|
Market Cap | $2.35B | $44.82B |
Sector | Health | Industrials |
52-Week High | $8.12 | $248.73 |
52-Week Low | $2.78 | $126.29 |
Enterprise Value | $1.99B | $44.58B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ODFL trades at $215.51, down 0.98% today, with technical indicators showing a bearish trend near support at $214. The company maintains strong fundamentals with a Q1 2026 EPS beat of $1.14 versus $1.05 expected, though revenue declined to $5.5B in 2025. Valuation remains elevated with a P/E of 45.18 and P/S of 8.35, while profitability metrics like ROE of 23.33% and net margin of 18.46% highlight operational efficiency.
The outlook is mixed: analyst consensus targets $230.69 with 33% buy ratings, but near-term risks include Amazon's LTL expansion (Barron's, June 10, 2026) and high valuation concerns. Cash flow stability and debt-free balance sheet support long-term potential, though investors face headwinds from freight market volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
